Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases.
about
New insights into the determination of HDL structure by apolipoproteins: Thematic review series: high density lipoprotein structure, function, and metabolismTyrosine modifications in agingVIPP1 Has a Disordered C-Terminal Tail Necessary for Protecting Photosynthetic Membranes against StressStructure and dynamics of human apolipoprotein CIIIDouble Superhelix Model of High Density LipoproteinLessons from making the Structural Classification of Proteins (SCOP) and their implications for protein structure modellingRole of lipids in spheroidal high density lipoproteinsSmall cytoskeleton-associated molecule, fibroblast growth factor receptor 1 oncogene partner 2/wound inducible transcript-3.0 (FGFR1OP2/wit3.0), facilitates fibroblast-driven wound closureThe C terminus of apolipoprotein A-V modulates lipid-binding activity.Switch region for pathogenic structural change in conformational disease and its predictionTemplated spherical high density lipoprotein nanoparticles.The helix bundle: a reversible lipid binding motifSerum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins.Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I.Disruption of the C-terminal helix by single amino acid deletion is directly responsible for impaired cholesterol efflux ability of apolipoprotein A-I Nichinan.Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol exportActivation of lecithin:cholesterol acyltransferase by HDL ApoA-I central helices.The N-terminus of apolipoprotein A-V adopts a helix bundle molecular architecture.Nuclear import by karyopherin-βs: recognition and inhibitionAssessment of the validity of the double superhelix model for reconstituted high density lipoproteins: a combined computational-experimental approach.Identification of sites in apolipoprotein A-I susceptible to chymase and carboxypeptidase A digestion.The N-terminus of the intrinsically disordered protein α-synuclein triggers membrane binding and helix folding.HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilutionThe adipophilin C terminus is a self-folding membrane-binding domain that is important for milk lipid secretionStructural analysis of nanoscale self-assembled discoidal lipid bilayers by solid-state NMR spectroscopy.Conformational transitions in the membrane scaffold protein of phospholipid bilayer nanodiscsMaking water-soluble integral membrane proteins in vivo using an amphipathic protein fusion strategy.High density lipoprotein structure-function and role in reverse cholesterol transport.The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?Structural analysis of reconstituted lipoproteins containing the N-terminal domain of apolipoprotein BNaturally occurring variant of mouse apolipoprotein A-I alters the lipid and HDL association properties of the protein.The "beta-clasp" model of apolipoprotein A-I--a lipid-free solution structure determined by electron paramagnetic resonance spectroscopy.Validation of previous computer models and MD simulations of discoidal HDL by a recent crystal structure of apoA-I.Optimized negative-staining electron microscopy for lipoprotein studies.Structure, function and amyloidogenic propensity of apolipoprotein A-I.ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity.The specific amino acid sequence between helices 7 and 8 influences the binding specificity of human apolipoprotein A-I for high density lipoprotein (HDL) subclasses: a potential for HDL preferential generationA three-dimensional homology model of lipid-free apolipoprotein A-IV using cross-linking and mass spectrometry.Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia.Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segment
P2860
Q26851804-B15E8E8B-9D43-4ADB-A20D-691EEB60E4CCQ26998450-2D16F624-1E37-4C2E-A037-1536B9D508E4Q27319818-A5B7F58F-4739-41AF-8795-9681D8FB071CQ27650312-E1B2C8A8-4D1F-470C-9C94-E74448582A07Q27657720-8EE81A59-E38F-4594-ABFF-875D3C3212A0Q28074771-C687A380-CA29-4132-8A4F-5C850C96FCFDQ28475955-5A42F448-7946-42AD-8447-F5046B79CA7EQ28573399-60F21CFC-85C6-4F1B-9A6C-FA90DBA43EBBQ30360807-51040ABC-4AAD-4FD2-997E-CBD4F1404E0DQ30384993-2DF749B7-89DE-4C81-96A6-BC5C1B5A6D79Q33398727-C460D7C1-7A49-4FD2-96F0-8197D15DADE7Q33598704-DD2C674C-BA3B-41B8-AC92-872134796EABQ33693897-D1292AD0-659B-4655-875F-1155F3E3BD7EQ33719586-2B63FEC0-791C-4CD4-9FAB-ECA5CACC3B09Q33741251-E1E636A7-3D06-4450-8D77-90F80349E36DQ33902023-61B980F3-1E0E-4E0B-8AA6-1A9B4C3C0065Q33937174-739B95C3-E8C1-40E3-B766-2A691EE73E20Q33946941-DB5307E0-6637-4044-A2A7-EC509A41C758Q34024485-32B3DB40-7706-46CA-BAA2-2C1D0B526F72Q34412842-81C8E7CD-4405-47A3-9B1E-09D83167E964Q34448664-C1C7A53E-07ED-4984-B203-BD74A421A975Q34590797-530464E6-09B9-41B0-9E34-9CE1046CF04FQ35001010-A804CAF2-11DF-4706-8736-43212AFBF101Q35067813-F820469A-6EB2-4D2D-A7A9-F4C107FA622BQ35121263-F002C293-9DE4-4C21-ABAC-F974004A5079Q35264725-D88FA88A-82C0-4CBB-A3E3-7C74C9B87ED1Q35486995-7C365861-101F-44F5-AF00-F10B09C91079Q35547011-57064DEA-C189-4E74-99CD-03725CC444BAQ35692746-65D75E52-2A6C-4E94-8686-59F32E26E9B4Q35794585-EC901D87-502C-4538-86BF-0F8E1B5D87FDQ35897053-FB127817-01F5-4F9E-8F87-A83B3B15D49DQ36109412-256A8838-C6B2-4D64-9698-5D3E9D7FAD43Q36145214-E4195857-473D-4E03-A2DE-A846312BEFBEQ36429042-F2BFECE0-FF70-43BE-95BB-7C4731DDD87DQ36654590-37A3A1D8-BDDC-4C55-BA10-A37900875E1EQ36683234-E31B3F94-D3E8-4C36-9B9F-9F76E603F15FQ36701853-8D36DFBA-B91C-4734-9301-7D75BA8A86D3Q36719213-05182DF7-035D-4F80-A2AB-069C0684EAF4Q36744086-2D0D6656-D8C3-4EAC-ADC8-C3D4B1955219Q36745069-099D5188-3084-49CA-A40C-BABD7BAAF821
P2860
Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Crystal structure of human apo ...... ainst cardiovascular diseases.
@ast
Crystal structure of human apo ...... ainst cardiovascular diseases.
@en
Crystal structure of human apo ...... ainst cardiovascular diseases.
@nl
type
label
Crystal structure of human apo ...... ainst cardiovascular diseases.
@ast
Crystal structure of human apo ...... ainst cardiovascular diseases.
@en
Crystal structure of human apo ...... ainst cardiovascular diseases.
@nl
prefLabel
Crystal structure of human apo ...... ainst cardiovascular diseases.
@ast
Crystal structure of human apo ...... ainst cardiovascular diseases.
@en
Crystal structure of human apo ...... ainst cardiovascular diseases.
@nl
P2093
P2860
P356
P1476
Crystal structure of human apo ...... gainst cardiovascular diseases
@en
P2093
A Abdul Ajees
G M Anantharamaiah
H M Krishna Murthy
M Mahmood Hussain
P2860
P304
P356
10.1073/PNAS.0506877103
P407
P577
2006-02-01T00:00:00Z